AstraZeneca plc stock (GB0009895292): US drug approvals keep pharma giant in focus

Recent US drug approvals and oncology milestones have put AstraZeneca back in the spotlight, while investors assess the pipeline’s potential and the stock’s role in the global pharma sector.

AstraZeneca plc has returned to the forefront of investor attention after several recent US drug approvals and a notable oncology milestone payment related to its collaboration with Daiichi Sankyo, underscoring the strength of its late-stage pipeline and US market exposure, according to Ad-hoc-news as of 05/2026.

On the stock side, AstraZeneca shares remain actively traded in both London and New York, reflecting the group’s role as one of the largest global pharmaceutical companies by market value, as shown on the company’s listing overview on the London Stock Exchange and US ADR market data, according to London Stock Exchange as of 05/2026.

As of: 20.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: AstraZeneca
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: Cambridge, United Kingdom
• Core markets: Global, with significant exposure to the United States, Europe and emerging markets
• Key revenue drivers: Oncology, cardiovascular, renal & metabolism, respiratory, vaccines and immune therapies
• Home exchange/listing venue: London Stock Exchange (AZN); US ADRs on Nasdaq/NYSE
• Trading currency: Primarily GBP in London; USD for US-listed ADRs

AstraZeneca plc: core business model

AstraZeneca focuses on the research, development and commercialization of prescription medicines in areas with high unmet medical need, including oncology, cardiovascular, renal and metabolic diseases, respiratory conditions and rare diseases, as described in its corporate overview, according to AstraZeneca company website as of 03/2026.

The group’s model centers on high-value innovative therapies supported by significant investment in R&D, including biologics and targeted small molecules, often developed through both in-house research and external partnerships with peer pharma groups and biotech companies, according to AstraZeneca annual report as of 03/2025.

Commercially, AstraZeneca relies on a diversified geographic footprint, with substantial sales generated in the United States alongside Europe and key emerging markets such as China, helping balance regional pricing, reimbursement dynamics and regulatory environments, according to the same annual disclosure, as reported by AstraZeneca annual report as of 03/2025.

Main revenue and product drivers for AstraZeneca plc

In recent years, oncology has become the largest therapeutic area for AstraZeneca, driven by blockbuster and fast-growing cancer medicines targeting breast, lung and hematologic malignancies, which have been highlighted as key contributors to group revenue, according to AstraZeneca annual report as of 03/2025.

Beyond oncology, the company generates substantial sales from cardiovascular, renal and metabolic treatments, as well as respiratory and immunology products, which provide a diversified base that can partially offset patent expiries or competitive pressures in individual indications, according to AstraZeneca results release as of 02/2025.

The group’s pipeline is reinforced by strategic collaborations, including its long-standing partnership with Daiichi Sankyo in antibody-drug conjugates for oncology, which recently triggered a milestone payment of around $155 million following clinical and regulatory progress in the US, according to Ad-hoc-news as of 05/2026.

Industry trends and competitive position

The global pharmaceutical sector is currently shaped by sustained demand for oncology and immunology therapies, alongside heightened regulatory scrutiny on pricing in the United States, a key market for AstraZeneca and its international peers, according to sector analysis summarized by Bloomberg as of 04/2026.

Within this landscape, AstraZeneca competes with large multinational drug makers, seeking differentiation through targeted therapies, biomarker-driven trials and combinations with immuno-oncology agents, while also managing competition from biosimilars and generics in older product lines, as outlined in the company’s strategic review, according to AstraZeneca capital markets materials as of 11/2024.

For US-focused investors, AstraZeneca’s listings in London and via ADRs, combined with its substantial US revenue share and participation in major indices, make the stock a liquid way to gain exposure to global pharma innovation with a notable tilt toward oncology and other specialty care areas, according to Investing.com as of 05/2026.

Conclusion

AstraZeneca plc remains a prominent global pharmaceutical group with a strong emphasis on oncology and other specialty care areas, supported by continued US drug approvals and milestone-related collaboration income. The stock offers US investors exposure to a diversified international pipeline and significant US revenue, alongside the usual sector risks related to regulation, pricing and clinical development outcomes. As with any large pharma name, future share performance will depend on execution in late-stage trials, regulatory interactions and the successful balancing of growth assets against patent expiries.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.